Lung cancer breakthrough? new drug cocktail trial aims to boost surgery success

NCT ID NCT05061550

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 24, 2026

Summary

This study tests several drug combinations given before and after surgery for early-stage non-small cell lung cancer. About 630 participants will receive immunotherapy drugs like durvalumab along with chemotherapy or other targeted agents. The goal is to see if these combos can eliminate more cancer cells and improve long-term outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Toulon, 83000, France
Research Site
RECRUITING

Little Rock, Arkansas, 72205, United States
Research Site
RECRUITING

Los Angeles, California, 90095, United States
Research Site
WITHDRAWN

Oakland, California, 94611, United States
Research Site
RECRUITING

New Haven, Connecticut, 06510, United States
Research Site
COMPLETED

Stuart, Florida, 34994, United States
Research Site
COMPLETED

Gainesville, Georgia, 30501, United States
Research Site
RECRUITING

Chicago, Illinois, 60637, United States
Research Site
WITHDRAWN

Baltimore, Maryland, 21201, United States
Research Site
RECRUITING

Baltimore, Maryland, 21231, United States
Research Site
RECRUITING

Boston, Massachusetts, 02215, United States
Research Site
COMPLETED

Saint Louis Park, Minnesota, 55426, United States
Research Site
RECRUITING

Omaha, Nebraska, 68124, United States
Research Site
RECRUITING

Buffalo, New York, 14263, United States
Research Site
RECRUITING

Cleveland, Ohio, 44195, United States
Research Site
RECRUITING

Pittsburgh, Pennsylvania, 15212, United States
Research Site
RECRUITING

Chattanooga, Tennessee, 37404, United States
Research Site
RECRUITING

Memphis, Tennessee, 38120, United States
Research Site
WITHDRAWN

Nashville, Tennessee, 37203, United States
Research Site
RECRUITING

Nashville, Tennessee, 37203, United States
Research Site
RECRUITING

Nashville, Tennessee, 37232, United States
Research Site
RECRUITING

Houston, Texas, 77030, United States
Research Site
RECRUITING

Houston, Texas, 77090, United States
Research Site
RECRUITING

Fairfax, Virginia, 22031, United States
Research Site
RECRUITING

Edmonds, Washington, 98026, United States
Research Site
RECRUITING

Seattle, Washington, 98104, United States
Research Site
RECRUITING

Ghent, 9000, Belgium
Research Site
COMPLETED

Ghent, 9000, Belgium
Research Site
RECRUITING

Roeselare, 8800, Belgium
Research Site
COMPLETED

Edmonton, Alberta, T6G 1Z2, Canada
Research Site
RECRUITING

Winnipeg, Manitoba, R3E 0V9, Canada
Research Site
RECRUITING

Montreal, Quebec, H2W 1S6, Canada
Research Site
RECRUITING

Montreal, Quebec, H2X 3E4, Canada
Research Site
RECRUITING

Avignon, 84902, France
Research Site
WITHDRAWN

Bobigny, 93009, France
Research Site
RECRUITING

Bordeaux, 33076, France
Research Site
RECRUITING

Limoges, 83000, France
Research Site
RECRUITING

Rennes, 35000, France
Research Site
RECRUITING

Rouen, 76031, France
Research Site
RECRUITING

Suresnes, 92150, France
Research Site
RECRUITING

Kecskemét, 6000, Hungary
Research Site
RECRUITING

Székesfehérvár, 8000, Hungary
Research Site
COMPLETED

Tatabánya, 2800, Hungary
Research Site
RECRUITING

Törökbálint, 2045, Hungary
Research Site
RECRUITING

Dublin, D07 R2WY, Ireland
Research Site
RECRUITING

Dublin, D08 NHY1, Ireland
Research Site
RECRUITING

Dublin, D09 V2N0, Ireland
Research Site
RECRUITING

Galway, H91 YR71, Ireland
Research Site
RECRUITING

Aviano, 33081, Italy
Research Site
RECRUITING

Brescia, 25123, Italy
Research Site
WITHDRAWN

Catanzaro, 88100, Italy
Research Site
RECRUITING

Florence, 50134, Italy
Research Site
RECRUITING

Genova, 16100, Italy
Research Site
RECRUITING

Meldola, 47014, Italy
Research Site
RECRUITING

Milan, 20162, Italy
Research Site
RECRUITING

Monza, 20900, Italy
Research Site
RECRUITING

Padova, 35128, Italy
Research Site
RECRUITING

Perugia, 06156, Italy
Research Site
RECRUITING

Pisa, 56124, Italy
Research Site
RECRUITING

Roma, 00144, Italy
Research Site
RECRUITING

Rozzano, 20089, Italy
Research Site
RECRUITING

Lisbon, 1099-023, Portugal
Research Site
RECRUITING

Lisbon, 1169-050, Portugal
Research Site
RECRUITING

Lisbon, 1400-038, Portugal
Research Site
RECRUITING

Lisbon, 1500-650, Portugal
Research Site
WITHDRAWN

Porto, 4099-001, Portugal
Research Site
COMPLETED

Porto, 4100-180, Portugal
Research Site
RECRUITING

Porto, 4200-072, Portugal
Research Site
COMPLETED

Busan, 48108, South Korea
Research Site
WITHDRAWN

Chungcheongbuk-do, 28644, South Korea
Research Site
RECRUITING

Seongnam-si, 13496, South Korea
Research Site
RECRUITING

Seoul, 03080, South Korea
Research Site
RECRUITING

Seoul, 05505, South Korea
Research Site
RECRUITING

Suwon, 16247, South Korea
Research Site
RECRUITING

Suwon, 440-746, South Korea
Research Site
RECRUITING

A Coruña, 15006, Spain
Research Site
RECRUITING

Alicante, 03010, Spain
Research Site
RECRUITING

Barcelona, 08036, Spain
Research Site
RECRUITING

Barcelona, 8035, Spain
Research Site
RECRUITING

Córdoba, 14004, Spain
Research Site
RECRUITING

Madrid, 28040, Spain
Research Site
RECRUITING

Majadahonda, 28250, Spain
Research Site
RECRUITING

Málaga, 29010, Spain
Research Site
RECRUITING

Reus, 43204, Spain
Research Site
RECRUITING

Seville, 41009, Spain
Research Site
RECRUITING

Terrassa, 08221, Spain
Research Site
RECRUITING

Valencia, 46010, Spain
Research Site
RECRUITING

Liuying, 736, Taiwan
Research Site
RECRUITING

New Taipei City, 235, Taiwan
Research Site
RECRUITING

Tainan, 70403, Taiwan
Research Site
RECRUITING

Taipei, 10002, Taiwan
Research Site
RECRUITING

Taipei, 11217, Taiwan
Research Site
RECRUITING

Ankara, 06010, Turkey (Türkiye)
Research Site
RECRUITING

Ankara, 06500, Turkey (Türkiye)
Research Site
RECRUITING

Ankara, 06800, Turkey (Türkiye)
Research Site
RECRUITING

Istanbul, 34722, Turkey (Türkiye)
Research Site
RECRUITING

Izmir, 35575, Turkey (Türkiye)

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Volrustomig, Rilvegostomig, plus chemotherapy

What this could lead to

If successful, this could lead to better treatment options for early-stage lung cancer, potentially improving survival and reducing recurrence after surgery.

What could go wrong

This is an early Phase 2 trial, so results are not yet proven. The drug combinations may cause serious side effects, and not all participants may benefit.

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON SMALL CELL LUNG CANCER